AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) January 9, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced the completion of a USD 19 million (SEK 205 million) Series A extension […]
AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure, today announced that the clinical conduct of the first part of its GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) has been completed. Part A of GOAL-HF1 is a randomized, […]